Evidence map›Paper›PMID 32060034›Full record

ArticleBMJ open respiratory research2020

Laboratory-based Intermountain Validated Exacerbation (LIVE) Score stability in patients with chronic obstructive pulmonary disease.

Denitza P Blagev, Dave S Collingridge, Susan Rea, Kyle A Carey, Richard A Mularski, Siyang Zeng, Mehrdad Arjomandi, Valerie G Press

Erratum issuedAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Denitza P BlagevPulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah, USA denitza.blagev@imail.org.ORCID 0000-0003-0860-1153
Dave S CollingridgePulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah, USA.
Susan ReaPulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah, USA.
Kyle A CareySection of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA.
Richard A MularskiDepartment of Medicine, Kaiser Permanente Center for Health Research Northwest Region, Portland, Oregon, USA.
Siyang ZengMedicine, University of California San Francisco, San Francisco, California, USA.
Mehrdad ArjomandiMedicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-0116-9217
Valerie G PressMedicine, University of Chicago, Chicago, Illinois, USA.

Funding

Research Design, Data, and Analytics CoreP30DK092949 · NIDDK · UNIVERSITY OF CHICAGO · PI MILDA Renne SAUNDERS · 2011 to 2026
$10.0M
Bringing Respiratory Education for improved Adherence and Technique Home through E-interventions for Self-management (BREATHES) ProgramR03HL144883 · NHLBI · UNIVERSITY OF CHICAGO · PI PRESS, VALERIE G · 2018 to 2019
$162k
NHLBI NIH HHS R03 HL144883NIDDK NIH HHS P30 DK092949
6 · The paper itself

Abstract

backgroundThe Laboratory-based Intermountain Validated Exacerbation (LIVE) Score is associated with mortality and chronic obstructive pulmonary disease (COPD) exacerbation risk across multiple health systems. However, whether the LIVE Score and its associated risk is a stable patient characteristic is unknown.

methodsWe validated the LIVE Score in a fourth health system. Then we determined the LIVE Score stability in a retrospective cohort of 98 766 patients with COPD in four health systems where it was previously validated. We assessed whether LIVE Scores changed or remained the same over time. Stability was defined as a majority of surviving patients having the same LIVE Score 4 years later.

resultsThe LIVE Score separated patients into three LIVE Score risk groups of low, medium, and high mortality and LIVE Score stability. Mortality ranged from 6.2% for low-risk LIVE to 45.8% for high-risk LIVE (p<0.001). We found that low-risk LIVE groups were stable and high-risk LIVE groups were unstable. Low-risk LIVE group patients remained low risk, but few high-risk LIVE group patients remained high risk (79.0% high vs 48.1% medium vs 8.8% low, p<0.001 for all pairwise comparisons).

conclusionThe LIVE Score identifies three major clinically actionable cohorts: a stable low-risk LIVE group, an unstable high-risk LIVE group with high mortality rates, and a medium-risk LIVE group. These observations further our understanding of how existing data used to calculate the LIVE Score may target interventions across risk cohorts of patients with COPD in a health system.

Indexed as

Disease ProgressionSeverity of Illness IndexAdultAgedAged, 80 and overCause of DeathFemaleHumansMaleMiddle AgedPulmonary Disease, Chronic ObstructiveQuality of LifeRetrospective StudiesSurvival AnalysisTime FactorsUnited Statesclinical epidemiologyCOPD exacerbationsemphysemahealth economist

Identifiers

PMID32060034
PMCPMC7047500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.